Effect of dapagliflozin on heart failure with reduced ejection fraction in children

Objective: To explore the efficacy and safety of dapagliflozin therapy in children with heart failure with reduced ejection fraction. Methods: -blocker, and aldosterone receptor antagonist. Clinical characteristics, underlying diseases, cardiac function ratings, left ventricular ejection fraction, B-type natriuretic peptide, and blood biochemical indexes were collected. Changes in cardiac function ratings, left ventricular ejection fraction, and B-type natriuretic peptide at 24 (±2) weeks of treatment were observed; the incidence of hospitalization or death due to exacerbation of heart failure at 24 (±2) weeks of treatment was observed secondarily. Adverse medicine events such as hypoglycemia or hypotension were also observed during treatment. Results: = 0.071). Three children developed urinary tract infection during the administration of the medication, and three children developed hypotension, while no other adverse reactions, such as hypoglycemia or hepatic or renal function impairment, were observed. Conclusion: Dapagliflozin was associated with improvements in left ventricular ejection fraction, BNP, and NYHA cardiac function classification in children with heart failure with reduced ejection fraction. No hospitalization or death due to the deterioration of heart failure and no serious adverse reactions were observed. The treatment was generally well tolerated, and the weight-stratified dosing strategy showed acceptable short-term safety.